Ignite Creation Date:
2025-12-24 @ 10:04 PM
Ignite Modification Date:
2026-01-01 @ 11:45 PM
Study NCT ID:
NCT05283135
Status:
COMPLETED
Last Update Posted:
2025-10-24
First Post:
2022-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
High Dose Risankizumab for Psoriasis
Sponsor:
Oregon Medical Research Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-07-10
Completion Date Type:
ACTUAL
First Submit Date:
2022-02-03
First Submit QC Date:
None
Study First Post Date:
2022-03-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-01-23
Results First Submit QC Date:
None
Results First Post Date:
2025-10-24
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-09
Last Update Post Date:
2025-10-24
Last Update Post Date Type:
ESTIMATED